JP2006504658A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504658A5
JP2006504658A5 JP2004523812A JP2004523812A JP2006504658A5 JP 2006504658 A5 JP2006504658 A5 JP 2006504658A5 JP 2004523812 A JP2004523812 A JP 2004523812A JP 2004523812 A JP2004523812 A JP 2004523812A JP 2006504658 A5 JP2006504658 A5 JP 2006504658A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004523812A
Other languages
English (en)
Japanese (ja)
Other versions
JP4484703B2 (ja
JP2006504658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/050322 external-priority patent/WO2004011436A1/en
Publication of JP2006504658A publication Critical patent/JP2006504658A/ja
Publication of JP2006504658A5 publication Critical patent/JP2006504658A5/ja
Application granted granted Critical
Publication of JP4484703B2 publication Critical patent/JP4484703B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004523812A 2002-07-25 2003-07-18 キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用 Expired - Lifetime JP4484703B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
PCT/EP2003/050322 WO2004011436A1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors

Publications (3)

Publication Number Publication Date
JP2006504658A JP2006504658A (ja) 2006-02-09
JP2006504658A5 true JP2006504658A5 (enExample) 2006-04-27
JP4484703B2 JP4484703B2 (ja) 2010-06-16

Family

ID=31188461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004523812A Expired - Lifetime JP4484703B2 (ja) 2002-07-25 2003-07-18 キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用

Country Status (37)

Country Link
US (1) US7498343B2 (enExample)
EP (2) EP2301544B1 (enExample)
JP (1) JP4484703B2 (enExample)
KR (1) KR100733577B1 (enExample)
CN (2) CN101070304B (enExample)
AP (1) AP2421A (enExample)
AR (1) AR040673A1 (enExample)
AT (1) ATE463482T1 (enExample)
AU (1) AU2003262529B2 (enExample)
BE (1) BE2014C051I2 (enExample)
BR (1) BRPI0312927B8 (enExample)
CA (1) CA2493225C (enExample)
CY (3) CY1111882T1 (enExample)
DE (1) DE60332023D1 (enExample)
DK (2) DK2301544T3 (enExample)
EA (1) EA008937B1 (enExample)
ES (2) ES2343458T3 (enExample)
FR (1) FR14C0060I2 (enExample)
HR (2) HRP20050045B1 (enExample)
HU (1) HUS1400047I1 (enExample)
IL (2) IL166457A (enExample)
IS (1) IS2914B (enExample)
LU (1) LU92520I2 (enExample)
ME (1) ME00131B (enExample)
MX (1) MXPA05001052A (enExample)
MY (1) MY143564A (enExample)
NL (1) NL300684I2 (enExample)
NO (2) NO329935B1 (enExample)
NZ (1) NZ538391A (enExample)
PL (1) PL222801B1 (enExample)
PT (2) PT1527050E (enExample)
RS (1) RS52431B (enExample)
SI (2) SI1527050T1 (enExample)
TW (1) TWI323730B (enExample)
UA (1) UA82198C2 (enExample)
WO (1) WO2004011436A1 (enExample)
ZA (1) ZA200500680B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553266C (en) 2004-01-23 2013-03-12 Janssen Pharmaceutica N.V. Substituted quinolines and their use as mycobacterial inhibitors
PT1711181E (pt) * 2004-01-23 2009-12-29 Janssen Pharmaceutica Nv Derivados quinolina e sua utilização como inibidores micobacterianos
ES2306098T3 (es) * 2004-01-29 2008-11-01 Janssen Pharmaceutica Nv Derivados de quinolina para uso como inhibidores de micobacterias.
EA010651B1 (ru) * 2004-05-28 2008-10-30 Янссен Фармацевтика Н.В. Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
CN101065397B (zh) * 2004-09-28 2015-10-21 詹森药业有限公司 一种细菌atp合酶的结合结构域
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
RS52316B (sr) * 2005-05-25 2012-12-31 Janssen Pharmaceutica Nv Proces za pripremu (alfa s, beta r)-6-bromo-alfa-[2¬(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3¬kinolinetanola
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
MY173664A (en) * 2005-06-28 2020-02-14 Janssen Pharmaceutica Nv Quinoline derivatives as antibacterial agents
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
ES2607879T3 (es) 2012-04-27 2017-04-04 Janssen Pharmaceutica N.V. Derivados de quinolina antibacterianos
IN2014MN02364A (enExample) 2012-04-27 2015-08-14 Janssen Pharmaceutica Nv
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
BR112015014145B1 (pt) 2012-12-21 2020-12-29 Janssen Sciences Ireland Uc compostos antibacterianos, composição farmacêutica, seus processos de preparação e combinação
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
JP6362235B2 (ja) * 2014-07-14 2018-07-25 ツーセン ファーマシューティカル カンパニー リミテッド ピリジン誘導体およびその抗マイコバクテリウムにおける使用
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
AU2016212116B2 (en) 2015-01-27 2021-07-15 Janssen Pharmaceutica Nv Dispersible compositions
CN108347945B (zh) * 2015-04-29 2021-03-23 以色列农业和农村发展部农业研究组织(范卡尼中心) 抗植物致病组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
CN107848978B (zh) * 2015-07-24 2021-04-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN108699047B (zh) * 2016-03-03 2022-03-11 科学与工业研究委员会 作为抗分枝杆菌药剂的取代的橙酮生物碱
AU2017229128B2 (en) * 2016-03-07 2022-04-07 Janssen Pharmaceutica Nv Antibacterial compounds and uses thereof
CA3025727A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP3589323B1 (en) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Combination therapy for the treatment of tuberculosis
US11141384B2 (en) 2017-07-14 2021-10-12 Janssen Pharmaceutica Nv Long-acting formulations
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
MX2022003037A (es) 2019-09-13 2022-04-07 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CN112574175B (zh) * 2019-09-29 2023-11-14 南京长澳医药科技有限公司 喹啉类化合物、其制备方法和用途
CA3151712A1 (en) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
AU2020358643A1 (en) 2019-09-30 2022-05-26 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
US12383548B2 (en) 2019-12-27 2025-08-12 Tecnimede—Sociedade Técnico-Medicinal, SA Antibacterial quinolines
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
US20230355606A1 (en) 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
CN117396475A (zh) 2021-03-16 2024-01-12 爱尔兰詹森科学公司 抗菌化合物
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2023275744A1 (en) 2021-06-29 2023-01-05 TECNIMEDE - Sociedade Técnico-medicinal, SA Heterocyclic compounds for the treatment of tuberculosis
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006B (zh) * 2022-05-13 2026-02-13 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用
JP2025532272A (ja) 2022-09-28 2025-09-29 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型製剤
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
PE20251588A1 (es) * 2022-11-15 2025-06-16 Lilly Co Eli Agonistas de ahr
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria
WO2025181475A1 (en) 2024-02-27 2025-09-04 The University Of Liverpool Novel tuberculosis sterilization formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CA2293418A1 (en) * 1997-06-19 1998-12-23 Michael Z. Hoemann Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1999037365A1 (en) * 1998-01-23 1999-07-29 Fire Armour Pte Ltd. Nozzle with axially and perpendicularly directed apertures
EP1051413B1 (en) * 1998-01-26 2003-06-04 SmithKline Beecham plc Quinoline derivatives as antibacterials
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Similar Documents

Publication Publication Date Title
JP2006504658A5 (enExample)
CA2493225A1 (en) Quinoline derivatives and their use as mycobacterial inhibitors
CA2566544A1 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
US12357603B2 (en) Acyl sulfonamides for treating cancer
ES2858314T3 (es) Procedimiento para compuesto antifúngico
JP2008500992A5 (enExample)
JP2013532652A5 (enExample)
CA2553269A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
ES2967119T3 (es) Compuestos inhibidores de metaloenzimas
AU2015231226B2 (en) Antifungal compound process
JP2008535903A5 (enExample)
JP2017533968A5 (enExample)
JP2007505933A5 (enExample)
TW201840549A (zh) 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺
KR20150075114A (ko) 브루톤 티로신 키나제 억제제
JP2007511504A5 (enExample)
JP2011502958A5 (enExample)
JP2012513990A5 (enExample)
JP2009503024A5 (enExample)
JP2011526917A5 (enExample)
JP2006501201A5 (enExample)
JP2017502063A5 (enExample)
JP2004525183A5 (enExample)
JP2016508135A5 (enExample)
JP2012524110A5 (enExample)